Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

META Raises $15 Million to Develop Small Molecule Immunometabolism Drugs

publication date: Jun 13, 2022

META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. Using AI and its knowledge of immunometabolism biology, META develops first-in-class drugs by modulating cell metabolism to regulate the immune system, a new field for immune disorders. It expects to introduce drugs that have better potency and lower side effects than existing therapies. META developed its own AI technology for drug discovery while also using XtalPi’s AI platform. The investors include Forcefield Ventures, XtalPi, IMO Ventures and Tiantu Capital. META is incubated by Forcefield and XtalPi. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital